Floatz logo

Olaparib

Breast Inflammatory Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Breast Inflammatory Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Northwestern University
Phase 3BBB
TRASTUZUMAB
Hoffmann-La Roche
Phase 3BBB
Carboplatin
Northwestern University
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 3BBB
Docetaxel
Association Tunisienne de lutte Contre le Cancer
Phase 3BBB

View all 50 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →